Roundtable Roundup: Polling Physicians on Timing of Durvalumab in NSCLC
During separate virtual live events, David R. Gandara, MD, and Alexander Spira, MD, PhD, discussed the timing of durvalumab in non–small cell lung cancer from the PACIFIC trial with participating physicians.
“In your practice, what is the typical time to initiation of durvalumab following completion of concurrent chemoradiotherapy for patients with unresectable stage III non–small cell lung cancer?”
"I think 21 to 40 days is right where I would think we should be. I’m a little skeptical of giving durvalumab right at the completion of chemoradiation for a variety of reasons.”
—DAVID R. GANDARA, MD
Most of us are trying to get into that 4- to 6-week period. A couple of us try a bit earlier. I’ll tell you my experience is that patients need a little bit of a break, but I think we’re all pretty reasonable. I always say what I like to do is 21 to 40 days, but we always have people who are just not feeling well or need to go on that vacation [from therapy].”
—ALEXANDER SPIRA, MD, PHD
Key Trials From ASH 2024 Impact Treatment for Plasma Cell Disorders Going Forward
February 20th 2025Peers & Perspectives in Oncology editorial board member Marc J. Braunstein, MD, PhD, FACP, discussed the significant advancements in multiple myeloma treatment at the 2024 ASH Annual Meeting and Exposition.
Read More
